Invention Grant
- Patent Title: Oligonucleotide sequences targeting transcription factor TSC22D4 for the treatment of insulin resistance
-
Application No.: US15545104Application Date: 2016-02-12
-
Publication No.: US10676739B2Publication Date: 2020-06-09
- Inventor: Stephan Herzig , Mauricio Berriel Diaz , Tobias Schafmeier
- Applicant: Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts
- Applicant Address: DE Heidelberg
- Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS
- Current Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS
- Current Assignee Address: DE Heidelberg
- Agency: Saliwanchik, Lloyd & Eisenschenk
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@17b45f00
- International Application: PCT/EP2016/053050 WO 20160212
- International Announcement: WO2016/150618 WO 20160929
- Main IPC: C12N15/113
- IPC: C12N15/113 ; C12Q1/68
Abstract:
The present invention relates to oligonucleotide inhibitors of the TSC22D4 activity or expression and their uses for the prevention, treatment, and/or regulation of insulin resistance, metabolic syndrome and/or diabetes and/or for improving insulin sensitivity in a mammal.
Public/Granted literature
- US20180023078A1 Oligonucleotide Sequences Targeting Transcription FactorTSC22D4 for the Treatment of Insulin Resistance Public/Granted day:2018-01-25
Information query
IPC分类:
